Headline Roundup • July 20th, 2020
Oxford's Coronavirus Vaccine Trials Indicate Progress
Summary from the AllSides News Team
Featured Coverage of this Story
National Review (News)
An early human trial of Oxford University’s experimental coronavirus vaccine has yielded a strong immune response in hundreds of people, according to newly released data.
The potential vaccine, which the U.K. university developed in partnership with drugmaker AstraZeneca, was administered in a trial that involved 1,077 people and caused an immune response in people aged 18 to 55 that lasted two months or slightly longer, according to data published Monday by the medical journal The Lancet. The vaccine, which is made from a combination of coronavirus genetic material and a...
A UK vaccine against coronavirus has shown “promising” results, findings of the first phases of the study suggest.
The early-stage trial showed the vaccine is “safe, causes few side effects, and induces strong immune responses,” results published in The Lancet said.
However, scientists warned it is still too soon to know if the results are enough, and larger trials are currently under way.
The vaccine, developed by the University of Oxford, is called ChAdOx1 nCoV-19 and is delivered via a chimpanzee virus, called the vaccine vector.
It is made from...
Reuters
LONDON (Reuters) - An experimental coronavirus vaccine being developed by AstraZeneca and Oxford university was safe and produced an immune response in early-stage clinical trials, data showed on Monday, keeping alive the hope it could be in use by the end of the year.
The vaccine, called AZD1222, has been described by the World Health Organization’s chief scientist as the leading candidate in a global race to halt a pandemic that has claimed more than 600,000 lives.
More than 150 possible vaccines are in various stages of development with U.S....
.png)
